EDO-S101 is primarily investigated for its potential in cancer treatment, particularly in hematologic malignancies. It functions as a dual inhibitor, targeting both histone deacetylases (HDACs) and DNA alkylation, which can disrupt cancer cell growth and induce apoptosis. Clinical trials have explored its efficacy in treating relapsed or refractory multiple myeloma and other cancers, showing promise in enhancing therapeutic outcomes. Its unique mechanism of action makes it a candidate for combination therapies, potentially improving the effectiveness of existing treatments. Research continues to evaluate its safety, tolerability, and broader applications in oncology.